Clicky

  • Login
  • Register
  • Submit Your Content
  • Contact Us
Wednesday, August 21, 2024
World Tribune
No Result
View All Result
  • Home
  • News
  • Business
  • Technology
  • Sports
  • Health
  • Food
Submit
  • Home
  • News
  • Business
  • Technology
  • Sports
  • Health
  • Food
No Result
View All Result
World Tribune
No Result
View All Result

Novo Nordisk’s Wegovy wins UK approval for use to reduce heart risks

July 23, 2024
in News
Reading Time: 2 mins read
A A
Novo Nordisk’s Wegovy wins UK approval for use to reduce heart risks
0
SHARES
ShareShareShareShareShare

READ ALSO

Volatility spike was a ‘huge overreaction,’ but more could be ahead, strategist says

Japan trade on deck, Wall Street rally pauses

Novo Nordisk’s Wegovy weight loss drug has seen a meteoric rise in popularity. 

Nurphoto | Getty Images

LONDON — The U.K.’s health regulator on Tuesday approved the use of Novo Nordisk‘s Wegovy weight loss drug to reduce the risk of overweight and obese adults suffering from serious heart problems or strokes.

The new approval from the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) makes the Danish pharmaceutical giant’s GLP-1 obesity drug the first in the country to be prescribed for prevention of cardiovascular events in people with obesity.

It follows similar label expansion by the U.S. Food and Drug Administration in March.

Shares of Novo Nordisk were up after the announcement, trading 1.46% higher by 4:10 p.m. London time after pushing higher for much of the session.

The MHRA’s deputy director of innovative medicines, Shirley Hopper, said the decision marked an “important step forward” in combatting the effects of obesity.

Novo Nordisk’s Wegovy wins UK approval for use to reduce heart risks

“We’re assured that the appropriate regulatory standards of safety, quality and effectiveness for the approval of this medicine have been met,” Hopper said in a statement.

“This treatment option that prevents heart disease and strokes is an important step forward in tackling the serious health consequences of obesity,” she added.

Novo Nordisk’s blockbuster Wegovy injection was already approved in the U.K. for treatment of obesity and for weight management, to be used alongside diet, physical activity and behavioral support.

However, the new approval marks a major coup for the company as it seeks to move beyond Wegovy’s image as a “vanity drug” and fend off growing competition.

Results of a closely watched late-stage “SELECT” trial, published in August 2023, pointed to the drug’s efficacy in reducing major cardiovascular events by 20% compared with a placebo.

Obesity product competition is a 'win-win' for companies and society, Novo Nordisk CEO says

Credit: Source link

ShareTweetSendSharePin
Previous Post

Lego’s first Fortnite sets are here

Next Post

Ether ETFs: First day of trading

Related Posts

Volatility spike was a ‘huge overreaction,’ but more could be ahead, strategist says
News

Volatility spike was a ‘huge overreaction,’ but more could be ahead, strategist says

August 21, 2024
Japan trade on deck, Wall Street rally pauses
News

Japan trade on deck, Wall Street rally pauses

August 21, 2024
GMC targets electric truck leadership against Tesla, Ford, Rivian
News

GMC targets electric truck leadership against Tesla, Ford, Rivian

August 21, 2024
Brits snap up lower mortgages as BOE cut boosts market
News

Brits snap up lower mortgages as BOE cut boosts market

August 20, 2024
Eli Lilly weight loss drug cuts risk of developing diabetes in trial
News

Eli Lilly weight loss drug cuts risk of developing diabetes in trial

August 20, 2024
Who is Mike Lynch, UK tech entrepreneur missing in superyacht sinking?
News

Who is Mike Lynch, UK tech entrepreneur missing in superyacht sinking?

August 20, 2024
Next Post
Ether ETFs: First day of trading

Ether ETFs: First day of trading

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

What's New Here!

Kemin Food Technologies – North America Names Dr. Y. Joy Zhong as R&D Director

Kemin Food Technologies – North America Names Dr. Y. Joy Zhong as R&D Director

August 16, 2024
MAS sets up review group in bid to revive its SGX development

MAS sets up review group in bid to revive its SGX development

August 2, 2024
MLB legend Derek Jeter’s best business advice

MLB legend Derek Jeter’s best business advice

August 20, 2024
The Cybertruck is coming to Fortnite and Rocket League because we’re being punished

The Cybertruck is coming to Fortnite and Rocket League because we’re being punished

July 23, 2024
Boeing pleads guilty to fraud in fatal Max crashes

Boeing pleads guilty to fraud in fatal Max crashes

July 25, 2024
Yankees bolster bullpen by acquiring Mark Leiter Jr. in Cubs trade

Yankees bolster bullpen by acquiring Mark Leiter Jr. in Cubs trade

July 30, 2024
Germany’s struggling construction sector showing no signs of recovery

Germany’s struggling construction sector showing no signs of recovery

July 23, 2024

About

World Tribune is an online news portal that shares the latest news on world, business, health, tech, sports, and related topics.

Follow us

Recent Posts

  • Volatility spike was a ‘huge overreaction,’ but more could be ahead, strategist says
  • The EU wants no corner of the digital sphere left untouched, warning X and AI could be next
  • Kevin James recreates viral video in electric Mets moment
  • Japan trade on deck, Wall Street rally pauses

Newslatter

Loading
  • Submit Your Content
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • DMCA

© 2024 World Tribune - All Rights Reserved!

No Result
View All Result
  • Home
  • News
  • Business
  • Technology
  • Sports
  • Health
  • Food

© 2024 World Tribune - All Rights Reserved!

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In